<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04239690</url>
  </required_header>
  <id_info>
    <org_study_id>2018-00770</org_study_id>
    <nct_id>NCT04239690</nct_id>
  </id_info>
  <brief_title>Preservation of Blood in Extremely Preterm Infants</brief_title>
  <acronym>LIM</acronym>
  <official_title>A Randomised Controlled Intervention, Multi-centre Study Aiming to Preserve Blood Factors Using Micro-methods to Improve Development in Extremely Preterm Infants - &quot;Less is More&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Swedish Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current clinical protocols for blood sampling and analyses in extremely preterm infants rely
      on an infrastructure adapted to and developed for adult medicine. Excessive blood sampling
      volumes and the resulting loss of fetal blood components are related to neonatal morbidity.
      This randomised trial aims to provide evidence that preservation of blood using micro-methods
      results in decreased morbidity and increased quality of life in extremely preterm infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extremely preterm (EPT) infants are subjected to a sample-related withdrawal of whole blood
      of 50 % of total blood volume during the first 2 postnatal weeks and a transfused volume of
      100 % of total blood volume with donor blood during the corresponding time period. The
      resulting decrease in the proportion of fetal hemoglobin is strongly associated with
      morbidity outcome, especially broncho-pulmonary dysplasia (BPD), in the EPT infant.

      This randomized trial evaluates if a reduction in sample-related blood volume loss by 50%
      during the first two postnatal weeks leads to a reduced rate of BPD in EPT infants. Half of
      the included infants will be subjected to clinical blood sampling using micromethods during
      the first two postnatal weeks whereas blood sampling in the other half of infants will be
      performed using standard clinical methods.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallell assignment</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Prevalence and severity of BPD at 36 weeks post-menstrual age is determined by the oxygen challenge test performed by a trained respiratory nurse blinded to treatment at each study site.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Broncho-pulmonary dysplasia</measure>
    <time_frame>Broncho-pulmonary dysplasia is determined at a postmenstrual age of 36 weeks</time_frame>
    <description>Requirement of supplemental oxygen as determined by the oxygen challenge test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebral intraventricular haemorrhage</measure>
    <time_frame>Ultrasound at postnatal day 3, 7, 21 and 40 weeks postmenstrual age</time_frame>
    <description>Stage II, III and IV (Periventricular hemorrhagic infarction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necrotizing enterocolitis</measure>
    <time_frame>From birth until 40 weeks postmenstrual age</time_frame>
    <description>Stage 2-3, Bells criteria (X-ray + clinical signs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusions</measure>
    <time_frame>Blood transfusions administered during the first two postnatal weeks</time_frame>
    <description>Administered blood transfusions (ml/kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal Hemoglobin</measure>
    <time_frame>% of fetal hemoglobin at 7 and 14 postnatal days</time_frame>
    <description>% of fetal hemoglobin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>Micromethods for blood sample analysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood gases are analysed using 0.045 ml whole blood Levels of CRP are analysed using 0.010 ml whole blood</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard clinical methods for blood sample analysis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Blood gases are analysed using 0.3 ml whole blood Levels of CRP are analysed using 0.5 ml whole blood</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Micromethods for blood sample analysis</intervention_name>
    <description>Micromethods in the intervention arm are applied aiming to achieve a mean reduction of 50 % of sampled blood volume during the first two postnatal weeks as compared to standard clinical blood sampling analyses</description>
    <arm_group_label>Micromethods for blood sample analysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  gestational age &lt; 27 weeks at birth

        Exclusion Criteria:

          -  major malformation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Ley, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University, Lund, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Ley, MD, PhD</last_name>
    <phone>+46709264524</phone>
    <email>david.ley@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva Morsing, MD, PhD</last_name>
    <phone>+46708788442</phone>
    <email>eva.morsing@med.lu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Neonatal Intensive Care Unit</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Ley, MD, PhD</last_name>
      <phone>004646178440</phone>
      <email>david.ley@med.lu.se</email>
    </contact>
    <contact_backup>
      <last_name>Eva Morsing, MD, PhD</last_name>
      <phone>0046178449</phone>
      <email>eva.morsing@med.lu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 19, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extremely preterm infant</keyword>
  <keyword>Blood sampling</keyword>
  <keyword>Blood transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

